Palatin Technologies, Inc. (0KF3) Earnings Call Transcript & Summary

May 17, 2022

London Stock Exchange GB Health Care Biotechnology earnings 25 min

Earnings Call Speaker Segments

Operator

operator
#1

Good day, everyone, and welcome to the conference call on Palatin's operating results for the third quarter of fiscal year 2022. Please note that this call is being recorded. Before we get into our remarks, I want to point out that anything Palatin states which is not a historical fact could constitute a forward-looking statement. Such statements rest on assumptions that might or might not turn out to be accurate, and actual results could differ materially from what is anticipated because of the various risks and uncertainties covered in the company's latest filings with the Securities and Exchange Commission. As you evaluate these forward-looking statements regarding Palatin's prospects, we ask that you weigh those risks and uncertainties carefully. At this point, I'll hand the call over to our host, Dr. Carl Spana, Palatin's President and Chief Executive Officer. Please go ahead.

Carl Spana

executive
#2

Thanks, and good morning everyone — welcome to the call for Palatin's third quarter of fiscal 2022. Dr. Carl Spana here; I serve as CEO and President of Palatin. Joining me today is Steve Wills, who is Palatin's Executive Vice President, Chief Financial Officer, and Chief Operating Officer. Steve will begin by walking us through the financials along with other corporate updates. Steve.

Steve Wills

executive
#3

Thank you, Carl, and good morning to everyone. Turning to the financial results for the third quarter, which ended March 31, 2022, and beginning with revenue. Our total revenue is made up of gross product sales of Vyleesi — Palatin's FDA-approved product for premenopausal women with hypoactive sexual desire disorder — plus those Vyleesi gross product sales net of allowance and accruals, along with license and contract revenue. For the quarter ended March 31, 2022, gross product sales of Vyleesi to pharmacy distributors came to $1.3 million, with net product revenue of $216,000, versus gross product sales of $1.8 million and net product revenue of approximately $89,000 in the comparable quarter of 2021. Compared with that comparable quarter of 2021, gross product sales fell 27% while net product revenue rose 144%. Now on operating expenses: total operating expenses for the quarter ended March 31, 2022 were $8 million, against $6.6 million in the comparable quarter of 2021. That rise in operating expenses came from higher research and development expenses, mainly tied to our ongoing pivotal phase 3 clinical trial of PL9643, which was partly offset by lower commercial expenses related to Vyleesi. As for cash flows, Palatin's net cash used in operations for the quarter ended March 31, 2022 was $9.5 million, compared with net cash used in operations of $3.5 million for the same period in 2021.

Steve Wills

executive
#4

This rise mostly reflects a $4.3 million payment that came in during March 2021 tied to the termination agreement we have with AMAG, partly offset by higher operating expenses. Turning to net loss, Palatin recorded a net loss of $7.6 million, or $0.03 per basic and diluted common share, for the quarter ended March 31, 2022, versus a net loss of $5.7 million, or $0.02 per basic and diluted common share, in the same period of 2021. As I noted earlier, the bigger net loss stemmed chiefly from higher operating expenses. On Palatin's cash position as of March 31, 2022, cash and cash equivalents stood at $37.7 million, together with $0.8 million of accounts receivable, compared with $47.3 million in cash and cash equivalents plus $0.6 million of accounts receivable as of December 31st, 2021, and $60.1 million in cash and cash equivalents plus $1.6 million of accounts receivable as of June 30th, 2021. Under our current operating plan, we believe existing cash and cash equivalents, together with the $15 million of net proceeds raised from our recent private placement of preferred stock, assuming conversion to common stock or debt, will be enough to fund currently anticipated operating expenses through at least calendar 2023.

Steve Wills

executive
#5

To get a bit more granular on Vyleesi: during the quarter that closed on March 31st, 2022, gross product sales rose 67% versus the quarter before that — the one ending December 31st, 2021. Net product revenue was up 200% compared with that same prior quarter. Total prescriptions dispensed climbed 20% quarter over quarter. Refill rates, commercial insurance reimbursement, and net revenue for each prescription dispensed all went up relative to the previous quarter — and honestly, relative to every comparable quarter in sequence since we took over. Before handing things back to Carl, I want to touch on one more item: the $15 million preferred offering we announced last week. On May 11, 2022, Palatin signed a securities purchase agreement with institutional investors, selling and issuing 8.1 million shares of Series B convertible stock along with 900,000 shares of Series C convertible preferred stock. Both the Series B preferred stock and the Series C preferred stock carried a purchase price of $1.67 per share and can be converted into Palatin common stock at an initial conversion price of $0.45. Investors in the Series B preferred stock and the Series C preferred stock also got warrants allowing them to buy up to roughly 1.67 million shares of common stock at an exercise price of $0.50.

Steve Wills

executive
#6

Those 1.67 million common warrants for purchasing common shares worked out to roughly 5% warrant coverage. The offering's total gross proceeds, prior to subtracting offering expenses, come to $15 million. Palatin anticipates convening a stockholders meeting to request approval for, among other things, an amendment to our certificate of incorporation that would authorize a reverse stock split. Series B preferred stock and Series C preferred stock holders may vote solely on the reverse stock split and on any adjournment of that meeting connected to the reverse split. If those Series B or Series C shares get converted into common shares or redeemed for debt — which is what we expect — the company will apply such net proceeds toward working capital and general corporate purposes. Just looking over my notes here. That covers it. Carl, I'll hand things back to you.

Carl Spana

executive
#7

Thank you, Steve. When it comes to Vyleesi, we've been working toward improving the key metrics that underpin the drug's commercial worth. During the quarter, as Steve mentioned, we recorded substantial gains in gross sales, product revenue, prescriptions, and refills. Those ongoing improvements across Vyleesi's core metrics strengthen our capacity to re-license Vyleesi to a dedicated partner, which would secure its continued availability as a treatment option for premenopausal women with hypoactive sexual desire disorder, along with a return on our investment. We're still in discussions with prospective partners in the U.S. and other territories, and when a possible license might happen depends on securing acceptable terms with the right partner. In many inflammatory and autoimmune diseases, there's still a vital medical need for new therapies that give patients and clinicians safe and effective options. Our R&D operations concentrate on creating drugs that modulate the melanocortin system, a novel treatment modality for patients who suffer from pathological inflammation, with a primary focus on ophthalmic diseases such as diabetic retinopathy and dry eye disease. A lot of today's treatments for inflammatory and autoimmune diseases function by blocking one or more pro-inflammatory pathways, which can lead to immune suppression and major safety concerns.

Carl Spana

executive
#8

When we target the melanocortin system — which is among the body's built-in ways of resolving inflammation — we're able to bring the immune system back to a normal state and encourage tissue healing. Our belief is that going after the melanocortin system could result in highly differentiated therapeutics that offer efficacy along with a better safety profile. At a molecular level, our scientists are pushing forward the understanding of this system, and they're working to establish clinical validation for therapeutics based on melanocortin. Ocular and non-ocular indications are both part of our clinical development programs, which are built to show how broadly useful the melanocortin system can be as a new target for drug development. Should this succeed, we will have created a new class of therapeutics for treating inflammatory and autoimmune diseases. Our most advanced melanocortin agonist for ocular diseases affecting the tissues of the anterior, or front, of the eye is topically delivered PL9643. Dry eye disease is the first indication for PL9643, and enrollment began in December 2021 in a pivotal phase 3 dry eye disease study known as MELODY-1. In patients with moderate to severe dry eye disease, MELODY-1 is assessing the safety and efficacy of PL9643 against vehicle control across a 12-week treatment period. The study aims to enroll 240 patients and features an interim data assessment conducted by an independent data monitoring committee, which will let us raise the number of subjects if needed and thereby lower the risk of an underpowered study.

Carl Spana

executive
#9

The three co-primary endpoints plus three key secondary endpoints are going to consist of the signs and symptoms of dry eye disease, and those were chosen after a detailed analysis of the phase 2 data. Right now, MELODY-1 is enrolling patients across multiple sites in the U.S., and the interim data assessment remains on schedule for mid-2022, with preliminary data expected in the second half of 2022. Should that succeed, Palatin will launch the second phase 3 study of PL9643 in dry eye disease, known as MELODY-2, along with an open-label safety study called MELODY-3. All three of the MELODY PL9643 dry eye disease studies are built to generate the safety and efficacy data needed for a new drug application filing with the FDA. PL9643's emerging profile — rapid therapeutic onset, excellent ocular tolerability, and a strong safety profile — represents a potentially distinct step forward in dry eye disease therapy. If the phase 2 results hold up in the upcoming phase 3 clinical study, we believe PL9643 could achieve substantial penetration into the multi-billion dollar dry eye disease market. We also believe that PL9643 and other melanocortin agonists will prove useful in treating multiple front of the eye disease indications, and we are planning to move a second front of the eye disease indication forward to an investigational new drug filing in 2022 as well.

Carl Spana

executive
#10

Turning now to the back of the eye: PL9654 is a melanocortin agonist being developed to treat multiple forms of retinopathy. At present, we are carrying out the preclinical work needed to submit an investigational drug application to the FDA, which would let us launch clinical activities with PL9654. We recently shared preclinical data at the 2022 annual meeting of the Association for Research in Vision and Ophthalmology, describing the protective effects of PL9654 in animal models of retinopathy. The existing market for FDA-approved retinopathy drugs came to roughly $20 billion in 2021 and is expected to exceed $27 billion by the end of 2025. A substantial need persists for innovative new therapies for retinal diseases. Although PL9654 is early in development, we believe it holds tremendous potential to benefit patients with retinal disease and to form a significant part of this extremely large market. Our oral PL8177 is a selective melanocortin-1 receptor agonist being developed to treat ulcerative colitis. We remain on schedule to begin patient enrollment in a phase 2 proof of concept study during the second quarter of 2022. We expect initial data to read out by early 2023. This will be our first clinical study intended to assess the potential of a selective melanocortin-1 receptor agonist as a treatment for inflammatory bowel diseases.

Carl Spana

executive
#11

This study is going to assess how safe and how effective PL8177 is, and its findings will strengthen the case that the melanocortin system works as a target for innovative medicines, while also backing our business development and licensing work for oral PL8177. More details about our science and our programs are available on our website, www.palatin.com. We're in a strong position to move forward a new mechanism for treating inflammatory and autoimmune diseases, built on drugs that modulate the melanocortin system. This year is an exciting one for Palatin, with data readouts coming from two major clinical programs and further programs moving toward clinical studies. Before we get to the Q&A session, just to recap: PL9643 is actively enrolling patients in a phase 3 pivotal dry eye disease study called MELODY-1, and we've already enrolled more than the 120 patients required for the interim assessment, which stays on schedule for mid-2022, with data by year-end. PL8177 for treating ulcerative colitis remains on schedule to start patient enrollment in the second quarter of 2022 in a phase 2 proof of concept clinical study, with preliminary data by early 2023. Our pipeline of innovative new treatments keeps growing, with PL9654, a novel melanocortin agonist for treating retinopathies, moving toward an investigational new drug filing, along with a novel melanocortin agonist for a second front of the eye treatment, which is also advancing toward an IND filing.

Carl Spana

executive
#12

On the Vyleesi commercial side, we keep seeing meaningful gains in the key measures — insurance reimbursement, net revenue for each prescription, and refills. Through our communications work, Palatin is becoming known as a company that is developing promising new therapies for ocular diseases. Looking ahead to the rest of 2022, Steve and I are energized by the huge opportunity in front of us to move forward a portfolio of innovative, highly differentiated drugs that will make a positive difference for patients and build shareholder value. Thank you for joining our call and for your continued support. Carl and I are ready to take questions.

Operator

operator
#13

Thanks. Everyone, to ask a question, just hit star one on your phone's keypad. Should you be on speakerphone, kindly verify that your mute is disabled so the signal can get through to our equipment. Once more, star one if you want to pose a question. We'll hold briefly while the phone queue is put together. Our first question comes from Joe Pantginis at H.C. Wainwright. Go right ahead.

Sara Nik

analyst
#14

Hi, and thanks for taking our questions. This is Sara Nik on for Joe. My first question is about PL9643. You did mention that you're looking into a second front-of-the-eye indication. I was wondering if you could give us some insight into which indications you're currently assessing to study.

Carl Spana

executive
#15

Absolutely. It won’t actually be PL9643 — we’ll be advancing a different melanocortin agonist instead. The indications could span everything from post-surgical use, you know, cataract surgery or lens surgery, through to glaucoma. Even though glaucoma isn’t traditionally considered front of the eye, I put it in that category since it’s usually managed with topical eye drops. Those are a few of the indications we’re evaluating as a follow-on to dry eye disease.

Sara Nik

analyst
#16

All right, thanks a lot. And turning now to PL8177 in ulcerative colitis — I realize the study will be starting shortly. I was hoping you might be able to elaborate a bit on what sets this particular agent apart from the other treatments currently on the market for UC.

Carl Spana

executive
#17

Right. PL8177 is built to act on the colon topically. It's a peptide contained in an oral formulation that gets released once the drug reaches the colon. A polymer coating surrounds it, shielding it from digestion until release happens at the proper location. Our approach targets melanocortin-1 receptors located on epithelial cells of the lumen, on the side facing the colonic lumen. As you can see here, this drug isn't absorbed systemically, which makes it very safe. So what we have is the possibility of delivering efficacy along with an extremely favorable safety profile. We're not doing any immune suppression here. In ulcerative colitis and other inflammatory bowel diseases, once you get beyond first-line therapy, you then move to steroids or immunomodulators or biologics, and all of those deliver some degree of efficacy and certainly represent a huge market. Ultimately, they're all mainly administered systemically, and they carry immunosuppressive properties that come at a pretty high cost, both economically and from a medical or safety standpoint. We truly have the potential here to offer a safe, effective treatment option that doesn't really exist today in the IBD space, and it certainly would be ideally suited for pediatric patients, where you don't necessarily want patients progressing as young adults onto really severe immune suppressive treatments that essentially probably won't have a great outcome for them over a number of years.

Sara Nik

analyst
#18

Oh, okay. Thanks. And one last thing — is there going to be an interim assessment for this trial?

Carl Spana

executive
#19

Yeah, both this trial and the dry eye study use somewhat adaptive designs. Once the first 16 patients have gone through, we’ll carry out an interim assessment and check whether any adjustments are needed — to the kinds of patients we’re enrolling, the timing of endpoint assessment, and so forth. You know, the real aim of the study is a pure proof of concept, and it’s really built to give us the information, first, to demonstrate that the drug does indeed have significant efficacy so we can move forward, and second, to identify which types of patients and endpoints fit this mechanism best.

Sara Nik

analyst
#20

All right, thanks a lot.

Operator

operator
#21

Our next question comes from Michael Higgins at Ladenburg Thalmann. Go right ahead.

Farhana Shamsi

analyst
#22

Hi there, Farhana Ali here, speaking for Michael Higgins. We’ve got 4 questions. I suppose this is mainly a follow-up regarding phase 2 for PL8177. Could you share a bit more detail? How many patients do you anticipate? And which primary endpoints are you considering?

Carl Spana

executive
#23

Okay. We're evaluating somewhere in the range of 30 to 32 patients. If we observe meaningful efficacy and want to increase that figure, we definitely have the ability to do so. The endpoint we're focused on is mucosal healing. The treatment duration in this case is 8 weeks, and what we're seeking is evidence of mucosal healing through colonoscopy, and of course we'll also examine a range of other components of the Mayo Score as they relate to clinical outcomes too.

Farhana Shamsi

analyst
#24

Alright, thanks a lot. I’ve got one more question about the front-of-the-eye condition. When should we expect that IND? You said it would be disclosed in 2022, but can you give us any sense of the timing on that?

Carl Spana

executive
#25

That’s going to happen late in the year.

Farhana Shamsi

analyst
#26

Thanks.

Carl Spana

executive
#27

It'll be more toward the end of the year. At the moment, we have a number of opportunities we want to pursue and several compounds that we're able to advance. What we're doing right now is really finishing up some of the final preclinical evaluations, and then Steve and his team are matching that up with the commercial side. When we evaluate some of these opportunities, we don't just ask, okay, what does the science support? What is the preclinical evidence showing? How do we translate that clinically? We then pair that with regulatory strategy and, overall, what represents the best opportunity based on the market opportunity, risk-adjusted profiles, and so on and so forth. All of those things are underway at present. We'll probably come out in early third quarter with the indication, and from there we'll complete. If you look at the front of the eye, the preclinical tox requirements are fairly straightforward, and we'll get those finished and get an application in to start studies by the end of the year.

Farhana Shamsi

analyst
#28

Alright, great. Just a couple of fast questions. For PL-9654, does the IND remain on schedule for 2022? And then on PL-3994, is the Part eight data still expected during the first half of 2022?

Carl Spana

executive
#29

On the latter one, yes — that's for PL-3994. And yes, we would for PL-9654. If I said our IND filing would be in 2022, I stand corrected — it would actually be in 2023. Keep in mind that diabetic retinopathy, or any of the retinopathies, involves long-term systemic treatments, so long-term tox is required before you can begin. We're preparing to launch that program — the long-term tox — and completing it will take anywhere from 9-plus months. We wouldn't move forward without it. With the front of the eye, treatment runs about 12 weeks, so the tox program is considerably shorter. For the back of the eye, advancing a compound makes no sense unless you finish all the longer-term tox in two species, which takes roughly 9 months of in-life work, and then you receive your reports and can file. That's set to begin probably in late Q3 or early Q4, and from there you add 12 months for an IND filing.

Farhana Shamsi

analyst
#30

All right, excellent. Thanks. We really appreciate you answering our questions.

Carl Spana

executive
#31

Appreciate it.

Operator

operator
#32

Our next question comes from John Newman at Canaccord. Go ahead, please.

John Newman

analyst
#33

Hello, gentlemen. Thanks for taking my question. I just have a question about the MELODY-1 study. I was wondering whether you could remind us how you'll be handling the endpoint analysis there. I believe you said before that there's some flexibility regarding which sign and which symptom you need to hit in order to show statistical significance.

Carl Spana

executive
#34

That is a great question, and I appreciate you bringing that up, John. The problem with dry eye disease is that the patient population is very broad. What drives their condition, or the underlying disease state, varies a great deal. In clinical trials, variability isn't something we're especially fond of. To tackle that, we haven't restricted ourselves to one primary endpoint or one secondary endpoint. We have three co-primaries — two signs and one symptom — plus three key secondaries, which are two symptoms and one sign. The aim is to capture a sign and a symptom within the same trial, since that really lets you run just two studies and then file with the FDA. From a statistical analysis perspective, we split the alpha, so rather than 0.05, we'd need to reach the key primary at one-third of that, 0.0167. As the study is built, if we achieve a single one of the co-primaries, we can preserve the statistical hierarchy and proceed to examine the key secondaries. If we achieve one of the key secondaries, we're able to keep moving forward and carry on with the analysis.

Carl Spana

executive
#35

So the design works like this: if we get a sign on the key primary and a symptom on the key secondary, that counts as both a sign and a symptom within the same tr-study. From there, we can use that for a submission, or the reverse. If instead the symptom lands in the co-primary and the sign shows up in the key secondary, we're equally fine. This really hands us several routes forward, so we don't have to box ourselves in with only a sign or only a symptom as the endpoint. Beyond that, the interim assessment is tied to this approach — suppose, for instance, we get a sign in the primary spot but miss the symptom; then they'll examine how many additional patients we'd need to enroll in order to reach the key secondary symptom. We've genuinely incorporated every possible belt and suspenders, drawing on everything modern clinical trial design offers, to handle the variability across these studies and give us the strongest shot at lowering our risk and being able to deliver your 2 phase three studies with the sign and symptom in both.

John Newman

analyst
#36

All right, that's excellent. Thanks very much.

Operator

operator
#37

Ladies and gentlemen, that brings today's question and answer session to a close. Right now, I'd like to hand the conference back over to Dr. Carl Spana for any additional remarks or closing comments.

Carl Spana

executive
#38

Steve and I want to express our appreciation to all of you, and I'd also like to thank everyone for joining us on this third quarter 2022 conference call. There are several significant items on the horizon in the next couple of quarters. We're eager to keep all of you updated. That said, enjoy the rest of your day, and we'll speak with you again before long. Bye-bye.

Operator

operator
#39

Ladies and gentlemen, that brings today's conference to a close. Thank you for joining us. You're welcome to disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Palatin Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Palatin Technologies, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Palatin Technologies, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.